Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Heartbeam Inc (BEAT)

Heartbeam Inc (BEAT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
HeartBeam (NASDAQ: BEAT) Reports Q4 and Full-Year 2024 Financial Results, Highlights FDA Clearance and Commercial Progress

HeartBeam (NASDAQ: BEAT), a medical technology company focused on advanced cardiac care, announced its financial and operational results for the fourth quarter and full-year 2024. The company achieved...

BEAT : 2.0100 (+3.61%)
HeartBeam (NASDAQ: BEAT) to Present at Upcoming Investor and Industry Conferences

HeartBeam (NASDAQ: BEAT), a medical technology company focused on advancing cardiac care, announced that CEO Robert Eno and CFO Timothy Cruickshank will participate in two upcoming conferences in Dana...

BEAT : 2.0100 (+3.61%)
HeartBeam (NASDAQ: BEAT) to Report Q4 and Full-Year 2024 Results on March 13

HeartBeam (NASDAQ: BEAT) announced it will release its fourth quarter and full-year 2024 financial results on March 13, 2025, and host a conference call at 4:30 p.m. ET. The call will include updates on...

BEAT : 2.0100 (+3.61%)
HeartBeam (NASDAQ: BEAT) Underwriter Exercises Option, Increasing Gross Proceeds to $11.5M

HeartBeam (NASDAQ: BEAT), a medical technology company focused on advancing cardiac care, announced that the underwriter of its recent public offering exercised its option to purchase an additional 864,033...

BEAT : 2.0100 (+3.61%)
HeartBeam (NASDAQ: BEAT) Prices $10 Million Public Offering at $1.70 Per Share

HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care, announced the pricing of its public offering of 5,882,353 shares at $1.70 per share, expecting to raise $10 million before...

BEAT : 2.0100 (+3.61%)
HeartBeam (NASDAQ: BEAT) Submits FDA Application for 12-Lead ECG Synthesis Software

HeartBeam (NASDAQ: BEAT), a medical technology company advancing cardiac care, has submitted a 510(k) application to the U.S. Food and Drug Administration (“FDA”) for its 12-lead electrocardiogram...

BEAT : 2.0100 (+3.61%)
HeartBeam (NASDAQ: BEAT) to Present at JP Morgan 2025 Annual Healthcare Conference

HeartBeam (NASDAQ: BEAT), a medical technology company revolutionizing cardiac care, announced its participation in the JP Morgan 2025 Annual Healthcare Conference, set for Jan. 13-16, 2025, in San Francisco....

JPM : 248.12 (-1.16%)
BEAT : 2.0100 (+3.61%)
HeartBeam (NASDAQ: BEAT) to Present at JP Morgan 2025 Annual Healthcare Conference

HeartBeam (NASDAQ: BEAT), a medical technology company revolutionizing cardiac care, announced its participation in the JP Morgan 2025 Annual Healthcare Conference, set for Jan. 13-16, 2025, in San Francisco....

JPM : 248.12 (-1.16%)
BEAT : 2.0100 (+3.61%)
HeartBeam (NASDAQ: BEAT) Presents Positive Data for Groundbreaking Tech at AHA Conference

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, today announced the results from two studies...

BEAT : 2.0100 (+3.61%)
HeartBeam (NASDAQ: BEAT) Advances Toward Commercialization of Cardiac Care Tech with FDA Submissions

HeartBeam (NASDAQ: BEAT), reported steady progress in its third quarter financial and operational results, advancing its cardiac care technology through key FDA 510(k) submissions and strategic leadership...

BEAT : 2.0100 (+3.61%)

Barchart Exclusives

Marjorie Taylor Greene Loves This High-Yield Dividend Stock. Should You Buy It Too?
Congresswoman Marjorie Taylor Greene’s recent investment in Devon Energy has brought attention to the stock, which boasts a strong financial performance, attractive valuation, and growing dividend. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar